Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Turrini

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
British Journal of Haematology|April 30, 2020
Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell diseasePanae Noomuna, Mary Risinger, Sitong Zhou, et al.
Anti-Cancer Drugs|August 21, 2002
Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trialB Neri, L Doni, C Fulignati, et al.
British Journal of Cancer|August 22, 2002
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II studyB Neri, G Cini, L Doni, et al.
Multiple Sclerosis and Related Disorders|July 31, 2023
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factorsM Petracca, A Carotenuto, C Scandurra, et al.
Nature|February 18, 2026
Reduced cyclin D3 expression in erythroid cells protects against malariaMaria Giuseppina Marini, Maura Mingoia, Maristella Steri, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
British Journal of Haematology|April 30, 2020
Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell diseasePanae Noomuna, Mary Risinger, Sitong Zhou, et al.
Anti-Cancer Drugs|August 21, 2002
Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trialB Neri, L Doni, C Fulignati, et al.
British Journal of Cancer|August 22, 2002
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II studyB Neri, G Cini, L Doni, et al.
Multiple Sclerosis and Related Disorders|July 31, 2023
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factorsM Petracca, A Carotenuto, C Scandurra, et al.
Nature|February 18, 2026
Reduced cyclin D3 expression in erythroid cells protects against malariaMaria Giuseppina Marini, Maura Mingoia, Maristella Steri, et al.
Pageof 3